- American City Business Journals•yesterday
Novavax isn't ready to give up just yet on what was once its most promising vaccine candidate — turned stunning failure last fall . On Thursday, Gaithersburg-based Novavax (NVAX) announced it started a new phase 2 clinical trial of the product, a vaccine candidate for respiratory synctial virus, or RSV, in older adults. The trial, which will enroll up to 300 older adults in the southern hemisphere, is meant to test the safety and ability of the vaccine candidate to provoke an immune response to both one- and two-dose regimens.
GAITHERSBURG, Md., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced the initiation of a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine ...
GAITHERSBURG, Md., Jan. 19, 2017-- Novavax, Inc. today announced the initiation of a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate in older adults.. ...
NVAX : Summary for Novavax, Inc. - Yahoo Finance
Novavax, Inc. (NVAX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||1.35 x 1000|
|Ask||1.37 x 12500|
|Day's Range||1.34 - 1.40|
|52 Week Range||1.16 - 8.49|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.21|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|